Decrease in cortical benzodiazepine receptors in symptomatic patients with leukoaraiosis - A positron emission tomography study
Decrease in cortical benzodiazepine receptors in symptomatic patients with leukoaraiosis - A positron emission tomography study
复制标题
DOI：
10.1161/01.str.0000122624.32167.e0
复制
发表时间：
2004-04-01
期刊：
影响因子：
8.3
通讯作者：
Fukuyama, H
中科院分区：
文献类型：
--
作者：
Ihara, M;Tomimoto, H;Fukuyama, H
背景和目的-[C-11]氟马西尼（FMZ）是一种选择性结合神经元膜中央苯二氮受体的配体，可用于正电子发射断层扫描（PET）中评估神经元活力。使用这种配体，我们调查是否有神经元的完整性之间的相关性，在各种脑结构和痴呆症患者leukoaraiois.Methods -12例广泛的脑白质疏松症的磁共振成像分为组或不痴呆的患者。基于包括代谢物校正的动脉输入和PET测量的脑放射性的2室、2参数模型，通过非线性曲线拟合计算FMZ在各个感兴趣区域中的分布容积（FMZ-V-d）。此外，示踪剂动力学分析应用于FMZ-V-d的逐体素定量，并通过统计参数mapping.Results进行数据分析-痴呆的存在与大脑皮层广泛区域的FMZ-V-d减少相关，包括双侧额极和额/岛区，左颞枕边界区，结论：大脑皮层神经元完整性的差异可能决定脑白质疏松症患者是否出现症状。
Background and Purpose -[C-11] flumazenil (FMZ), a ligand that selectively binds to the central benzodiazepine receptor in the neuronal membrane, is useful for evaluating neuronal viability in a positron emission tomography ( PET) scan. Using this ligand, we investigated whether there was a correlation between neuronal integrity in various brain structures and dementia in patients with leukoaraiosis.Methods - Twelve patients with extensive leukoaraiosis on magnetic resonance imaging were divided into groups of patients with or without dementia. Based on a 2-compartment, 2-parameter model that included metabolite-corrected arterial input and PET-measured cerebral radioactivity, the distribution volume of FMZ (FMZ-V-d) was calculated in various regions of interest by nonlinear curve fitting. Additionally, tracer kinetic analysis was applied for voxel-by-voxel quantification of FMZ-V-d, and data analysis was performed by statistical parametric mapping.Results - The presence of dementia was associated with a reduced FMZ-V-d in widespread areas of the cerebral cortex, including the bilateral frontopolar and frontal/insular areas, the left temporo-occipital border areas, and the left marginal cortical areas.Conclusions - Differences in neuronal integrity in the cerebral cortex might determine whether patients with leukoaraiosis become symptomatic or not.